<bill session="107" type="h" number="5350" updated="2013-07-14T18:58:47-04:00">
  <state datetime="2002-09-09">REFERRED</state>
  <status>
    <introduced datetime="2002-09-09"/>
  </status>
  <introduced datetime="2002-09-09"/>
  <titles>
    <title as="introduced" type="short">Prescription Affordability and Medicine Safety Act of 2002</title>
    <title as="introduced" type="official">To provide greater access to affordable pharmaceuticals, and for other purposes.</title>
  </titles>
  <sponsor id="400215"/>
  <cosponsors>
    <cosponsor id="400007" joined="2002-10-16"/>
    <cosponsor id="400087" joined="2002-10-09"/>
    <cosponsor id="400143" joined="2002-10-02"/>
    <cosponsor id="400502" joined="2002-10-02"/>
    <cosponsor id="400243" joined="2002-10-02"/>
    <cosponsor id="400295" joined="2002-10-02"/>
    <cosponsor id="400357" joined="2002-11-13"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2002-09-09">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2002-09-09">
      <text>Referred to House Energy and Commerce</text>
    </action>
    <action datetime="2002-09-09">
      <text>Referred to House Ways and Means</text>
    </action>
    <action datetime="2002-09-23">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
    <committee code="HSWM" name="House Ways and Means" activity="Referral, In Committee"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Actions and defenses"/>
    <term name="Administrative procedure"/>
    <term name="Administrative remedies"/>
    <term name="Business income tax"/>
    <term name="Commerce"/>
    <term name="Consent decrees"/>
    <term name="Costs"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug advertising"/>
    <term name="Drug approvals"/>
    <term name="Drug industry"/>
    <term name="Drugs"/>
    <term name="Economics and public finance"/>
    <term name="Federal employees"/>
    <term name="Forfeiture"/>
    <term name="Generic drugs"/>
    <term name="Government operations and politics"/>
    <term name="Government paperwork"/>
    <term name="Government publicity"/>
    <term name="Government trust funds"/>
    <term name="Health education"/>
    <term name="Income tax"/>
    <term name="Injunctions"/>
    <term name="Intellectual property"/>
    <term name="Labor and employment"/>
    <term name="Law"/>
    <term name="Medicare"/>
    <term name="Patent infringement"/>
    <term name="Patents"/>
    <term name="Pharmaceutical research"/>
    <term name="Pharmacies"/>
    <term name="Prescription pricing"/>
    <term name="Recruiting of employees"/>
    <term name="Research and development"/>
    <term name="Restrictive trade practices"/>
    <term name="Revolving funds"/>
    <term name="Science, technology, communications"/>
    <term name="Social welfare"/>
    <term name="Tax deductions"/>
    <term name="Taxation"/>
    <term name="User charges"/>
  </subjects>
  <amendments/>
  <summary>9/9/2002--Introduced.
Prescription Affordability and Medicine Safety Act of 2002 - Authorizes appropriations for the Food and Drug Administration (FDA) for generic drug application review and the continuation of the education program on the use and therapeutic equivalency of drugs.Amends the Public Health Service Act to authorize the Secretary of Health and Human Services to make grants to States in support of State pharmacy benefit assistance programs. Requires a percentage of profits from the sale of certain drugs and biological products to be placed in a revolving fund and used to support the grants program.Limits the tax deductions for advertizing for prescription drug manufacturers.Limits the extension of the 30 month stay of FDA approval for any new (generic) drug, as specified, thereby limiting the brand name drug's patent owner's period of exclusive sales.Makes a patent owner's failure to timely file a civil action for infringement a bar to later action.Sets forth requirements for filing drug patent information with the FDA. Makes a patent owner's failure to timely file with the FDA a bar to civil actions for patent infringement.Requires the first generic drug applicant with a specified certification to forfeit the 180 day marketing exclusivity period to a subsequent generic drug applicant if the first generic drug applicant engages in certain behaviors which delay or prevent the marketing of the generic drug.</summary>
</bill>
